Jardiance

Empagliflozin, the active ingredient in Jardiance, is a SGLT2 inhibitor presented as an oral dosage form for oral use. It is used to improve blood glucose control in adults with type 2 diabetes and to reduce cardiovascular risk in those with established cardiovascular disease.

GNH USA supplies Jardiance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jardiance acts on the sodium‑glucose co‑transporter 2 pathway to manage metabolic and cardiovascular conditions. - Type 2 diabetes mellitus: improves glycaemic control when added to diet and exercise. - Cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease: lowers risk of cardiovascular death. - Adjunct to diet and exercise: helps patients achieve target HbA1c levels as part of a comprehensive diabetes management plan.

Common side effects are generally mild and related to its mechanism of increasing urinary glucose loss.

Common Side Effects: - Urinary tract infection: symptoms such as dysuria or frequency. - Genital mycotic infection: itching or irritation in genital area. - Increased urination: polyuria leading to nocturia. - Thirst: polydipsia due to fluid loss.

Serious or Rare Side Effects: - Ketoacidosis: metabolic acidosis with elevated ketones. - Severe dehydration: may cause hypotension or renal impairment. - Acute kidney injury: sudden decline in renal function.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Renal function: assess eGFR and avoid use in severe renal impairment. - Hypotension: monitor blood pressure, especially in patients on diuretics. - Genital infections: counsel patients on hygiene and early symptom reporting. - Volume depletion: advise adequate fluid intake during illness or hot weather. - Store at room temperature: keep in the original package, protect from moisture and direct sunlight.

Empagliflozin may interact with other medicines that affect glucose, blood pressure, or renal function.

Major Interactions (Avoid): - Insulin or insulin secretagogues: increased risk of hypoglycaemia. - Loop diuretics: additive risk of volume depletion and hypotension. - Rifampin: may reduce empagliflozin exposure and efficacy.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Thiazide diuretics: may enhance hypotensive effect. - NSAIDs: watch for renal function changes.